6 completed, 1 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Unknown 1, Withdrawn 1 |
Follow methylnaltrexone: new trials by email Literature Review of methylnaltrexone trials Research Report on methylnaltrexone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer Methylnaltrexone bromide, Placebo - Pancreatic Cancer | Phase 2 / Phase 3 | Withdrawn | Bausch Health Americas, Inc. | 2020-01-06 | 2021-05-07 | |
| Subcutaneous Methylnaltrexone Versus Placebo for Postoperative Ileus Prevention Methylnaltrexone, Placebo - Postoperative Ileus | Phase 2 | Completed | Ohio State University | 82 | 2019-02-21 | 2021-10-27 |
| Study of Methylnaltrexone in Opioid-Induced Constipation Patients Methylnaltrexone (MNTX), Placebo - Opioid-induced Constipation | Phase 2 / Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 198 | 2015-04-01 | 2015-10-14 |
| Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Erythromycin, Methylnaltrexone - Gastroparesis | Phase 2 | Terminated | Shiraz University of Medical Sciences | 42 | 2010-05-01 | 2011-03-31 |
| Methylnaltrexone for Opioid-induced Constipation in Cancer Patients Methylnaltrexone bromide - Neoplasms, Constipation | Phase 2 | Completed | University of Vermont | 12 | 2009-10-01 | 2016-02-02 |
| Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures Methylnaltrexone bromide, Placebo - Opioid-induced Constipation | Phase 2 | Completed | Bausch Health Americas, Inc. | 37 | 2007-10-19 | 2019-09-04 |
| Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain N-methylnaltrexone bromide (MOA-728), placebo - Constipation | Phase 2 | Completed | Bausch Health Americas, Inc. | 122 | 2007-10-01 | 2020-08-20 |
| Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus IV Methylnaltrexone (MNTX), Placebo - Postoperative Ileus | Phase 2 | Completed | Bausch Health Americas, Inc. | 65 | 2003-07-01 | 2019-11-27 |
| Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone IV Methylnaltrexone - Healthy Volunteers | Phase 2 | Completed | Bausch Health Americas, Inc. | 12 | 2002-04-01 | 2019-11-27 |
Constipation (2) · Opioid-Induced Constipation (2) · Gastroparesis (1) · Ileus (1) · Neoplasms (1) · Opioid-Related Disorders (1) · Pancreatic Neoplasms (1)
Bausch Health Americas, Inc. (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Ohio State University (1) · Shiraz University of Medical Sciences (1) · University of Vermont (1)
United States (7) · China (1) · Iran (1)
Tage Ramakrishna, MD (2) · John Lahey (1) · Lindsey Mathew (1) · Shiying Yu, Professor (1) · Steven Ades, MD (1)